Health
Prejex Inc. joins hands with Polybond & World Trade Center, Pune, to make needle-less injections in India
§ Revolutionary venture brings in new drug delivery system via needle-less injections
§ It is a cutting-edge innovation that the medical fraternity has long been waiting for
Mumbai, 21th December 2022: Prejex Inc., a spin-off of Germany-based Prejex GMBH has entered into an agreement with Polybond, headed by Mr Adit Rathi of Rathi Group to manufacture needle-less injections. This partnership has enabled shifting of the manufacturing capabilities of the German company from Berlin to Pune, for global distribution. The Prejex-Polybond factory will make needle-less injections for the entire world.
The efforts of Mr. Niraj Khinvasara, CIO, World Trade Center, Pune, and Mr. Sagar Chordia, Chairman, World Trade Center Pune presented to Prejex a data-based analysis highlighting Pune as an industrial hub which includes over 250 German firms. The presentation focused on the decision of Mr. Maarten Stuut, MD of Prejex GMBH, and Mr. Harold Gerrits, Director of Global Sales and Distribution, to select India-especially Pune-as their preferred destination.
This FDI influx is a massive boost for Pune’s industrial capacity. India has a healthy medical ecosystem, which is a win-win situation for all the parties involved. World-class manufacturing units and long experience in medical manufacturing via subsidy company Eversure made Mr. Rathi the perfect partner for this revolutionary venture.
PREJEX: REVOLUTIONARY PRODUCT THAT THE WORLD WAS WAITING FOR
Prejex’s New Drug Delivery System (NDDS) via needle-less injections is a cutting-edge innovation that the medical world has long been waiting for. Prejex provides a solution to a variety of issues that professionals face in day-to-day operations. Syringes and disposable needles are major contributors to toxic waste and their disposal cost is sky-rocketing. Trypanophobia (fear of needles) is a common factor leading to the reluctance of patients in drawing of blood and receiving vaccines or intravenous fluids.
With Prejex’s entry, the pain factor is eliminated as the medicine is delivered subcutaneously through the skin which is an effective and reliable system. It also negates cross-contamination, ensuring the highest levels of safety and hygiene for doctors and patients alike. Being easy to use, even the patient can self-inject, reducing visits to the clinic and making
healthcare more cost-effective. It is also highly convenient for customized doses and application of a variety of drugs. The shelf life of the drugs is considerably increased due to the novel COC polymer syringes and plasticizer. Besides, it drastically cuts down on the use of disposable syringes, most of which are used by diabetic patients, thus adding to the sustainability factor (about 5.5% of the global population or 422 million people are diabetic).
New Drug Delivery System (NDDS) via needle-less injections is an exciting and revolutionary concept in pharma since it contributes to increased medication margins/revenues. Moreover, innovations in supply chain and delivery system make Prejex a pharmaceutical company with a superior edge.
Two different models to be launched
1. The N-Jector Series-a single-dose disposable device: Here, the dose is ‘pre-charged’ or ‘pre-filled’ in an ampoule and the device can easily be packed and disposed of once the dose has been administered. The device and/or ampoule can both be stored in a refrigerator or at room temperature.
2. The Prejex Multi-Reusable Device goes up to 30,000 clicks and is ideal for home use and/or self-administration. It is compatible with pre-filled and non-filled ampoules that can be attached easily via a simple twist.
A broad spectrum of applications can be covered using these needle-less injections:
§ DIABETES: Insulin and glucagon (antidote to insulin)
§ ENDOCRINOLOGY: Human growth hormone, octreotide etc.
§ ONCOLOGY SUPPORTIVE CARE: EPO and G-CSF (Filgrastim)
§ LOCAL ANAESTHETICS: Lidocaine, dental etc.
§ AUTOIMMUNE DISEASES: MTX, Humira, Remicade, Enbrel etc.
§ FERTILITY HORMONES: FSH, LH and HCG
§ ERECTILE DYSFUNCTION: Alprostadil, Trimix
§ VACCINES: HBV, HPV, Flu, MMR etc.
§ COSMETICS: Botox, Collagen, Hyaluronic Acid (HA) etc.
§ BIOSIMILAR: beta-IFN, Copaxone, IL-2, Herceptin and many others administered subcutaneously
The introduction of needle-less injections is bound to cause a reform in the delivery system of drugs in the near future. The combined efforts of Prejex, the Rathi Group and World Trade Center Pune, will hugely benefit the medical industry worldwide.
‘Prejex’s needle-less injections alleviate sufferings of patients’
‘Nearly 5% of the world is diabetic, that is, roughly 4.5-5 million people take 2 injections a day and companies like Prejex can alleviate pain and make life easier for patients. The medical sector is a critical segment for us. Prejex (Needleless Injections) is bringing to Pune a very innovative and strategic initiative by creating and fostering an ecosystem of medical innovation in India where we’re sourcing distributors, too’ -Niraj Khinvasara, CIO, World Trade Center, Pune
‘India on it’s way to becoming a global manufacturing hub for medical devices’
We are proud to be associated as the manufacturing partner for needleless injections for Prejex GmbH. This association is a true example of the ‘Make in India’ movement. Not only will European consumers get the benefit of European innovation combined by competitive Indian costs, such associations also accelerate the introduction of innovative products in the Indian market.
– Adit Rathi, Managing Director, Polybond India Pvt Ltd
